Bevacizumab does not elevate risk of neurodevelopmental impairment in cases of ROP

• Posted on: Sep 21 2021
• By: Saratoga Opthalmology
• Leave a response

This is the first meta-analysis evaluating the neurodevelopmental outcomes of bevacizumab therapy for retinopathy of prematurity (ROP).
Source: AAO

Posted in: Uncategorized